Physician profile
Bryan Picou
NPI 1922003656
$4,302.58
in general payments reported to CMS, 2019-2025
33 companies · $237 in 2025
The $237 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $585 · 2020: $661 · 2021: $893 · 2022: $244 · 2023: $700 · 2024: $983 · 2025: $237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,920.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,919.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Reapplix INC. | $742.22 | 2023-2024 | 3c Patch Kit - Box |
| Lilly USA, LLC | $421.88 | 2019-2024 | Mounjaro, Trulicity, Zepbound |
| Kerecis Limited | $421.07 | 2021-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Pfizer INC. | $317.20 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $286.06 | 2019-2025 | Farxiga, Breztri |
| Merck Sharp & Dohme LLC | $230.84 | 2019-2024 | Verquvo, Belsomra, Gardasil |
| Glaxosmithkline, LLC. | $196.93 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $196.30 | 2020-2025 | Ofev, Jardiance |
| Astellas Pharma US INC | $169.50 | 2019-2024 | Veozah |
| Novo Nordisk INC | $154.98 | 2020-2022 | |
| Paratek Pharmaceuticals, INC. | $131.42 | 2021-2025 | Nuzyra, Xhance |
| Xeris Pharmaceuticals, INC. | $116.06 | 2024-2025 | Keveyis, Gvoke Hypopen |
| Takeda Pharmaceuticals U.S.A., INC. | $82.92 | 2020-2022 | |
| Amarin Pharma, INC. | $78.38 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $68.72 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $68.04 | 2021 | |
| Allergan, INC. | $66.81 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $66.66 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $60.74 | 2022-2025 | |
| Amgen INC. | $59.91 | 2019-2024 | Prolia, Evenity, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.41 | 2020-2023 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $44.54 | 2020-2023 | |
| Abbvie INC. | $39.53 | 2021-2024 | |
| Eisai INC. | $36.16 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $31.31 | 2023-2024 | Rexulti |
| Integra Lifesciences Corporation | $30.45 | 2019 | |
| Exact Sciences Corporation | $29.96 | 2023-2024 | Cologuard Collection Kit |
| Tei Medical INC. | $29.61 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.83 | 2024 | Caplyta |
| Janssen Pharmaceuticals, INC | $15.54 | 2019 | |
| Mylan Specialty L.P. | $15.19 | 2021 | |
| Shield Therapeutics INC | $14.11 | 2024 | |
| Smith+Nephew, INC. | $12.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Picou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.